Brachytherapy

Papers
(The TQCC of Brachytherapy is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
PPP03 Presentation Time: 10:48 AM41
BP02 Presentation Time: 4:09 PM30
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM19
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM18
PHSOR06 Presentation Time: 9:25 AM16
PO042516
PO032416
MPP02 Presentation Time: 4:09 PM16
PPP02 Presentation Time: 10:39 AM15
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po14
BP08 Presentation Time: 5:03 PM14
PO041714
PO022714
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data12
GPP03  Presentation Time: 9:33 AM12
PHSOP2  Presentation Time: 9:05 AM12
PSOR12  Presentation Time: 5:25 PM11
PO3511
PO9311
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost11
Editorial Board11
PO4711
P010511
PSOR03  Presentation Time: 12:10 PM10
PSOR8  Presentation Time: 12:05 PM10
Association between rectal spacer use and bowel, urinary, and sexual dysfunction following prostate cancer brachytherapy: U.S. claims data analysis10
Evaluation of variability in applicator position and organs at risk dose in fractionated intracavitary brachytherapy for cervical cancer9
PL02 Presentation Time: 1:45 PM9
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications9
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study9
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy9
PO02499
PO04219
Author Index8
MSOR11 Presentation Time: 8:50 AM8
P03018
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients8
PRPP05  Presentation Time: 11:06 AM8
PO02348
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma7
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life7
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM7
GSOR14  Presentation Time: 11:35 AM7
Determination of the optimal time for planning SAVI brachytherapy for APBI7
The case for risk-stratified IORT for early breast cancer7
PO107
PP02  Presentation Time: 9:10 AM7
PPP04  Presentation Time: 10:57 AM7
MSOR12 Presentation Time: 8:55 AM7
Masthead7
PO46  Presentation Time: 4:45 PM7
Table of Contents7
GSOR04  Presentation Time: 12:15 PM6
PHSOR04  Presentation Time: 12:45 PM6
PO206
PO216
PHSOR05  Presentation Time: 12:50 PM6
MSPP03  Presentation Time: 4:20 PM6
PL02  Presentation Time: 1:45 PM6
PSOR02  Presentation Time: 4:35 PM6
Table of Contents6
PP05  Presentation Time: 5:06 PM6
Masthead6
PO04245
PO01095
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer5
Partial breast irradiation: An updated consensus statement from the American brachytherapy society5
High-dose-rate brachytherapy for airway malignancy a single institution experience5
MPP02  Presentation Time: 4:09 PM5
PO02415
PO02425
American Brachytherapy Society (ABS) rectoprostatic gel spacer consensus statement5
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?5
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
PSOR02 Presentation Time: 11:35 AM5
Skin Posters PO07015
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up5
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma5
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes5
Quantifying geometric and dosimetric advantage from the use of rectal spacing in HDR prostate brachytherapy5
PLANER: Development and validation of a real-time image-guided dynamic dosimetric framework for I-125 seed brachytherapy5
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM4
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle4
PO154
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy4
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
Comment on “high-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statement”4
Randomized trial comparing hypnosis versus standard management on patient anxiety and pain during pelvic brachytherapy applicator removal4
PP02  Presentation Time: 10:09 AM4
Comment on “How accurate is applicator reconstruction in HDR gynecological brachytherapy? Patient-specific results from an electromagnetic tracking system designed to intercept errors before radiation4
PO01194
PO914
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction4
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy4
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT4
Is single implant and multiple fractions radio-biologically iso-effective for cervical cancer high-dose-rate brachytherapy: Observation from patient cohorts during COVID pandemic4
GSOR13  Presentation Time: 12:30 PM4
PO194
PHSOR06  Presentation Time: 12:55 PM4
MSOP06  Presentation Time: 8:25 AM4
MSOP03  Presentation Time: 8:10 AM4
Development of a dosimetric phantom using OSLDs or TLD-100 for external audits of high-dose-rate 192Ir brachytherapy sources: Preliminary results4
Improving complex brachytherapy efficiency: Multidisciplinary quality assurance and workflow optimization4
PO1144
GPP06  Presentation Time: 11:15 AM4
PO33  Presentation Time: 10:30 AM3
PSOR7  Presentation Time: 12:00 PM3
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review3
PRSOP03  Presentation Time: 11:40 AM3
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer3
Development of a phantom and analysis of brachytherapy dosimetry using the sulfamic acid/electron paramagnetic resonance system3
Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma3
P03043
GSOR09 Presentation Time: 12:10 PM3
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent3
PP04  Presentation Time: 9:47 AM3
PO523
PO533
PSOR3  Presentation Time: 11:40 AM3
PO40  Presentation Time: 4:45 PM3
PPP05 Presentation Time: 11:06 AM3
Early outcomes of partial gland (focal) salvage brachytherapy for radiorecurrent prostate cancer3
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward3
Patterns of anesthesia(AS) and analgesia(AG) practice in gynecological brachytherapy in India3
PRPP02  Presentation Time: 10:39 AM3
PP05  Presentation Time: 11:36 AM3
PRSOP08  Presentation Time: 12:05 PM3
PO01103
Editorial Board3
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer3
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting3
PO03203
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM3
MSOR11 Presentation Time: 5:50 PM3
Effect of radiation dosage to vital ocular structures on visual outcomes: Re-evaluation for the future3
Dosimetric characterization and experimental validation for a low-kV FPXS electronic brachytherapy system3
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer3
GPP04  Presentation Time: 9:42 AM3
PO02613
PO02203
A novel dose-based intra-preplan method for high-dose-rate brachytherapy in cervical cancer using modeling and optimization algorithms3
PO863
PPP03  Presentation Time: 10:48 AM2
MPP05  Presentation Time: 4:36 PM2
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
Systematic review of brachytherapy for symptom palliation2
PO042
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment2
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada2
PO322
GSOR02  Presentation Time: 11:35 AM2
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)2
P01142
Accelerated partial breast irradiation with high-dose-rate multicatheter brachytherapy: 30-year results of a phase 2 clinical trial2
PO02292
PO04082
GSOR12 Presentation Time: 5:55 PM2
Rule-based AI automated adaptive treatment planning for image guided cervical cancer brachytherapy2
PO03102
MSS11  Presentation Time: 4:35 PM2
Combined operative and radiotherapeutic treatment for locally recurrent gynaecologic cancer with pelvic wall invasion: A monocentric retrospective study2
Letter to the editor regarding “Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy”2
Masthead2
PSOR06  Presentation Time: 12:25 PM2
Table of Contents2
Table of Contents2
What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?2
PHSOP6  Presentation Time: 9:25 AM2
Table of Contents2
PHSOR08  Presentation Time: 1:05 PM2
PO03142
MSPP05  Presentation Time: 4:40 PM2
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook2
PO492
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
PL03 Presentation Time: 2:00 PM2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
GSOR06 Presentation Time: 5:25 PM2
PO03112
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method2
Actinium-225 Targeted Agents: Where Are We Now?2
PO122
GSOR20  Presentation Time: 12:05 PM2
PO822
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry2
PO102
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy2
Outcomes and comparison of dosimetric parameters between intracavitary (Fletcher) and combined intracavitary/interstitial (Utrecht) brachytherapy in locally advanced cervical cancer2
PO02582
PO04282
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien2
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital2
GSOR10 Presentation Time: 12:15 PM2
GSOR06  Presentation Time: 11:55 AM2
PP02  Presentation Time: 8:29 AM2
PO01112
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy2
MSOR7 Presentation Time: 5:30 PM2
Masthead2
PO02332
MSOR9 Presentation Time: 5:40 PM2
PO27  Presentation Time: 7:40 AM2
GSOR23  Presentation Time: 12:20 PM2
GYN Posters PO012
PL04  Presentation Time: 2:15 PM2
Long-term oncologic outcomes of high-dose-rate interstitial brachytherapy (interventional radiotherapy) in oral tongue squamous cell carcinoma; 15 years of experience from a tertiary cancer center2
PP04  Presentation Time: 11:27 AM2
PP04 Presentation Time: 4:27 PM1
Inter-observer effects in needle reconstruction for temporary prostate brachytherapy: Dosimetric implications and adaptive CBCT-TRUS registration solutions1
Re: Letter to the editor with regards to “Impact of detector selection on commissioning of Leipzig surface applicators with improving immobilization in high-dose-rate brachytherapy” by Li et al.1
PO1001
Friday, June 17, 20222:30 PM - 3:30 PM PHSPP01  Presentation Time: 2:30 PM1
Brachytherapy outcome modeling in cervical cancer patients: A predictive machine learning study on patient-specific clinical, physical and dosimetric parameters1
Masthead1
GSOR05  Presentation Time: 12:20 PM1
Prostate Posters PO04011
PO051
Table of Contents1
PP05  Presentation Time: 4:06 PM1
Saturday, July 13, 202411:30 AM - 12:30 PMPSOR01 Presentation Time: 11:30 AM1
Randomized trial of dose de-escalation in low-risk prostate cancer patients implanted with Pd-1031
MSOR10 Presentation Time: 8:45 AM1
Long-term outcomes of salvage transurethral high-dose-rate brachytherapy combined with external beam radiation therapy for anastomotic recurrence of prostate cancer after radical prostatectomy: A retr1
Sunday, June 19, 2022 10:30 AM - 11:30 AMPP07  Presentation Time: 10:30 AM1
Long-term oncologic outcomes of low dose-rate brachytherapy compared to hypofractionated external beam radiotherapy for intermediate -risk prostate cancer1
PO1031
Comment on “Assessment of geometric distortions and dosimetric impact from implementing 2D-T2-PROPELLER and 3D-T1-LAVA-FLEX in an MRI-only gynecological brachytherapy workflow”1
PO03091
Masthead1
From patient to pioneer: The inspiring journey of Dr. Brian Moran1
PO171
PO30  Presentation Time: 10:30 AM1
Table of Contents1
Therapeutic and prophylactic effects of radiation therapy in the management of recurrent granulation tissue induced tracheal stenosis: a review on the role of Endobronchial brachytherapy and external 1
Comparing dosimetry of locally advanced cervical cancer patients treated with 3 versus 4 fractions of MRI-guided brachytherapy1
PSOR12 Presentation Time: 12:25 PM1
PO1191
PO131
Masthead1
PO28  Presentation Time: 7:40 AM1
PO1061
PO02631
MSOR7  Presentation Time: 5:15 PM1
Mortality and postinterventional complications after ablative treatment of liver malignancies: A cohort study of 4374 patients1
A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques1
PO111
GSOR08 Presentation Time: 5:35 PM1
PPP06 Presentation Time: 11:15 AM1
0.27795314788818